Crossmark

Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger’s disease)

Crossref DOI link: https://doi.org/10.1186/s13287-018-0901-6

Published Online: 2018-05-30

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Martin-Rufino, Jorge D.

Lozano, Francisco S.

Redondo, Alba M.

Villaron, Eva M.

Rueda, Raquel

Fernandez-Samos, Rafael

Sanchez-Guijo, Fermin https://orcid.org/0000-0002-7076-7739
License Information

Text and Data Mining valid from 2018-05-30
More Information

Article History

Received: 29 March 2018

Revised: 27 April 2018

Accepted: 10 May 2018

First Online: 30 May 2018

Ethics approval and consent to participate

: All the procedures reported were in accordance with the ethical standards of the 1975 Helsinki Declaration and its later amendments and were approved by the Ethics Committee of the Hospital Universitario de Salamanca (Spain). Informed consent was obtained from the MSC-treated TAO patient and the MSC donor. Appropriate approval was also obtained from the Spanish Medicines Agency (AEMPS).

: The patient’s written informed consent for publication was obtained.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.